Acute Megacolon

Back

Background

Megacolon, like megarectum, is a descriptive term. Megacolon denotes dilatation of the colon that is not caused by a mechanical obstruction. While the definition of megacolon has varied in the literature, most use a cecum measurement of greater than 12 cm in diameter to define megacolon. Adding to this definition, because the diameter of the large intestine is different in different areas, measurements of greater than 6.5 cm for the rectosigmoid region and greater than 8 cm for the ascending colon may also be significant.

Megacolon may be divided into three categories by acuity of onset, as follows: (1) acute megacolon (pseudo-obstruction); (2) chronic megacolon, which includes congenital, acquired, and idiopathic causes; and (3) toxic megacolon.

The Gastroenterology section of the Medscape Drugs & Diseases journal contains three articles devoted to megacolon, and they are separated based on the three aforementioned categories (see also Differentials). This article is devoted to the acute development of megacolon.

Pathophysiology

Whether dilatation is a result of abnormal motility of the colon remains unresolved. Much basic science research has been performed in this area. It is well known that the colonic distensibility changes in the presence of luminal contents. For example, fatty acids infused into the cecum appear to reduce the volume of the proximal large bowel. Long-term opiate narcotic use (including diphenoxylate and loperamide) may lead to colonic dilatation and may limit the ability of the colon to contract when dilated.

Many pathophysiologic mechanisms have been proposed in an attempt to explain the altered motility seen in acute megacolon; these include the following:

Etiology

Causes of acute megacolon include the following:

Note that in any setting, a mechanical cause (eg, a tumor) and a toxic cause (eg, acute ulcerative colitis) must be ruled out first because the treatments are very different for these conditions.

Epidemiology

United States data

No large-scale studies have been performed to determine the prevalence or incidence of acute megacolon.

Race-, sex-, and age-related demographics

Race and sex have not been documented to play a role in acute megacolon.

Most patients are middle-aged or older; however, the increased incidence seen in older populations is more likely a reflection of their medical and surgical comorbidities rather than age alone.

Prognosis

Mortality/morbidity

Prognosis is determined in part by the underlying cause of the megacolon, the presence of any comorbidities, and the development of complications.

The mortality rate associated with spontaneous perforation of nontoxic megacolon is 50%; however, most patients respond to treatment prior to the onset of this complication.[2]

Complications

The most severe complication is perforation with an associated mortality rate of approximately 50%. In a study by Vanek et al, the perforation rates were 0% for cecal diameters of less than 12 cm, 7% for cecal diameters of 12-14 cm, and 23% for cecal diameters of greater than 14 cm.[3]

Mortality was also shown to increase with a delay of decompression therapy.

If surgical therapy is required, mortality increases based on age, comorbidities, and functional status.

History

The typical patient is an elderly person who is in the hospital, usually for an unrelated reason (eg, recovering postoperatively from surgery), and may or may not already be taking oral feeds.

Orthopedic surgery, cesarean delivery, and cardiovascular or lung surgery are procedures that commonly predispose to acute megacolon.

Acute megacolon can occur on the medical wards as frequently as on the surgical wards (eg, in patients with unrelated problems, such as pneumonia, sepsis, myocardial infarction, or stroke).

Systemic diseases that affect the neuromuscular component of the GI tract, such as amyloidosis, may first present with an acute episode of pseudo-obstruction.

Not having a history of similar episodes of abdominal distension in the past is common.

Colic-type pain may be present, but the absence of this pain does not imply a less severe condition.

Patients often will experience nausea and vomiting as well as constipation and obstipation.

Physical Examination

Physical examination findings may include the following:

Laboratory Studies

Laboratory studies are directed at establishing the etiology of the acute megacolon as well as determining the patient's fluid status, and they include the following.

Imaging Studies

Imaging studies are used to determine the severity, to exclude free intraperitoneal air (perforation) as well as other etiologies (eg, extrinsic compression), and to follow the clinical course.[4]

Plain x-ray films of the abdomen demonstrate the massive gaseous distention of the colon. Generally, the small bowel is not seen. Dilation of all segments of the colon support the diagnosis of pseudo-obstruction.

Other imaging studies, such as hypaque (water soluble radiopaque contrast material) enema, CT scanning, or MRI, may also be used to exclude obstruction.

Procedures

Perform other tests only to rule out a mechanical obstruction. Depending on the setting, severity, and condition of the patient, these tests may include either a colonoscopic examination (which also may be therapeutic) or a water-soluble contrast enema. Colonoscopy is preferred because of its diagnostic and therapeutic potential.

Medical Care

Conservative management is preferred when the patient is clinically stable. Consider the following:

Decompression

Use of a rectal tube

Decompression using a rectal tube may assist in the treatment only if the sigmoid colon is involved. When such tubes are used, anecdotal experience has demonstrated that frequent position changes for the patient may help improve decompression. Complications with these rectal tubes include tube obstruction and colonic/rectal ulceration.

Colonoscopic decompression

If the dilatation persists or worsens, colonoscopic decompression with or without placement of a tube in the right colon should be considered. Although the placement of a decompression tube per rectum is generally suggested, some experts believe that the tube often becomes obstructed with stool and ceases to work after a short time. Randomized controlled trials of the efficacy of colonoscopic decompression are lacking. The resolution of ileus, perforation, and mortality rates are similar between endoscopic and conservative management.

Neostigmine

Neostigmine (adrenergic antagonist) has been demonstrated in noncontrolled and controlled studies to improve acute colonic megacolon. Whether a trial of neostigmine should be performed before or after colonoscopic decompression is unclear.

The major indication for its use is failure of conservative therapy after 72 hours. Failure of conservative therapy is generally defined by a cecal diameter of greater than 9 cm.

Contraindications include bradycardia, systolic blood pressure of less than 90 mm Hg, active bronchospasm, serum creatinine level of greater than 3 mg/dL, and evidence of bowel perforation.

Adverse events include abdominal cramping (17%), excessive salivation (13%), transient bradycardia (6%), diaphoresis (4%), and nausea and vomiting (4%). Based on expert opinion, a starting dose of 1 mg may reduce the likelihood of developing bradycardia.

Cardiac monitoring of patients during treatment with neostigmine is generally recommended, and atropine should be at the bedside.

A second dose of neostigmine should be considered if there is a partial or minimal response to the initial administration.

Of note, although neostigmine often induces clinical decompression, this decompression has not been shown to reduce perforation and mortality rates.

Urgency

The urgency of management often depends on the size of the colon and the rate of change of the cecal diameter. Some experts believe that regardless of the criteria used for defining acute megacolon, the diameter of the cecum is the most important criterion because the cecum is generally the area that perforates. While the diameter at which the cecum perforates is variable, expert experience indicates that the cecum rarely perforates at a diameter of less than 12 cm.

Hospitalization

Once relieved, close follow-up care, including physical examination and maintenance of a normal electrolyte balance, is important.

Avoid using agents that slow transit time, such as opiates and anticholinergics.

Diet and activity

Most patients are in the hospital when acute pseudo-obstruction is diagnosed, and bowel rest should be instituted. Parenteral nutrition may be considered depending on the patient's nutritional status.

Because many of the cases of acute pseudo-obstruction occur postoperatively, the patients tend to be already at bed rest. Remembering to continue prophylaxis for deep venous thrombosis, per the individual physician's protocol, is important; however, if the patient is not severely ill, is not in severe pain, and is stable to ambulate, no reason exists for the patient to remain in bed.

Surgical Care

In view of the high rate of recurrence of colonic dilation following medical and endoscopic therapies, other therapeutic modalities have been proposed.

Percutaneous cecostomy may successfully allow for colonic decompression, but complications with this procedure are high.

Surgical options include cecostomy, colostomy, or colectomy, although surgical therapies are associated with even poorer outcomes. A colectomy is indicated if perforation or colonic ischemia is present.[5]

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Neostigmine (Prostigmin)

Clinical Context:  Improves acute colonic megacolon; may increase cholinergic activity by reducing acetylcholine degradation.

Class Summary

Increase peristalsis and secretions in the intestine and relax the sphincter.

Author

Roberto M Gamarra, MD, Consulting Gastroenterologist, Digestive Health Associates, PLC

Disclosure: Nothing to disclose.

Coauthor(s)

David Manuel, MD, Affiliate Faculty, Department of Medicine, Loyola University Health System; Gastroenterologist, Digestive Health Center

Disclosure: Nothing to disclose.

Michael H Piper, MD, Clinical Assistant Professor, Department of Internal Medicine, Division of Gastroenterology, Wayne State University School of Medicine; Consulting Staff, Digestive Health Associates, PLC

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Douglas M Heuman, MD, FACP, FACG, AGAF, Chief of Hepatology, Hunter Holmes McGuire Department of Veterans Affairs Medical Center; Professor, Department of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine

Disclosure: Received grant/research funds from Novartis for other; Received grant/research funds from Bayer for other; Received grant/research funds from Otsuka for none; Received grant/research funds from Bristol Myers Squibb for other; Received none from Scynexis for none; Received grant/research funds from Salix for other; Received grant/research funds from MannKind for other.

Chief Editor

BS Anand, MD, Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous author, Clifford Y Ko, MD, MS, to the development and writing of this article.

References

  1. Tan CB, Rajan D, Shah M, et al. Toxic megacolon from fulminant Clostridium difficile infection induced by topical silver sulphadiazine. BMJ Case Rep. 2012 Aug 8. 2012:[View Abstract]
  2. Frasko R, Uchytil Z, Svab J, Vyborny J, Krska Z. [Treatment outcomes in patients with toxic megacolon]. Rozhl Chir. 2011 Jun. 90(6):339-42. [View Abstract]
  3. Vanek VW, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases. Dis Colon Rectum. 1986 Mar. 29(3):203-10. [View Abstract]
  4. Moulin V, Dellon P, Laurent O, Aubry S, Lubrano J, Delabrousse E. Toxic megacolon in patients with severe acute colitis: computed tomographic features. Clin Imaging. 2011 Nov. 35(6):431-6. [View Abstract]
  5. Antonopoulos P, Almyroudi M, Kolonia V, Kouris S, Troumpoukis N, Economou N. Toxic megacolon and acute ischemia of the colon due to sigmoid stenosis related to diverticulitis. Case Rep Gastroenterol. 2013 Sep 11. 7(3):409-13. [View Abstract]
  6. Camilleri M. Acute and chronic pseudo-obstruction. Felman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 8th ed. Philadelphia, PA: Saunders Publishing; 2007. 2679-2702.
  7. Fazel A, Verne GN. New solutions to an old problem: acute colonic pseudo-obstruction. J Clin Gastroenterol. 2005 Jan. 39(1):17-20. [View Abstract]
  8. Geller A, Petersen BT, Gostout CJ. Endoscopic decompression for acute colonic pseudo-obstruction. Gastrointest Endosc. 1996 Aug. 44(2):144-50. [View Abstract]
  9. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999 Jul 15. 341(3):137-41. [View Abstract]
  10. Saunders MD, Kimmey MB. Colonic pseudo-obstruction: the dilated colon in the ICU. Semin Gastrointest Dis. 2003 Jan. 14(1):20-7. [View Abstract]
  11. Stephenson BM, Morgan AR, Salaman JR, Wheeler MH. Ogilvie's syndrome: a new approach to an old problem. Dis Colon Rectum. 1995 Apr. 38(4):424-7. [View Abstract]
  12. Turegano-Fuentes F, Munoz-Jimenez F, Del Valle-Hernandez E, et al. Early resolution of Ogilvie's syndrome with intravenous neostigmine: a simple, effective treatment. Dis Colon Rectum. 1997 Nov. 40(11):1353-7. [View Abstract]
  13. Khajehnoori M, Nagra S. Acute colonic pseudo-obstruction (Ogilvie's syndrome) with caecal perforation after caesarean section. J Surg Case Rep. 2016 Aug 23. 2016(8):[View Abstract]
  14. Bargiela IS, Gomes MJ, Ferreira FB, Real AC, Ventura AS. A rare presentation of Ogilvie's syndrome. Eur J Case Rep Intern Med. 2019. 6(7):001175. [View Abstract]